Ruolan Chen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Ruolan Chen has a total of 32 co-authors. Here are the top co-authors by number of shared publications:
- Xian-Ming Chu
Department of Cardiology, The Affiliated Hospital of Qingdao University, Qingdao, China
4 shared publications - Bing Li
Department of Genetics and Cell Biology, School of Basic Medicine, Qingdao University, Qingdao, 266071, China
3 shared publications Xiaojian Xu
Department of Cardiology, The Affiliated Hospital of Qingdao University, No. 59 Haier Road, Qingdao, Shandong, 266100, China
3 shared publications- Xuezhe Wang
Department of Cardiology, The Affiliated Hospital of Qingdao University, Qingdao, China
3 shared publications - Guoliang Zhang
Department of Cardiology, The Affiliated Hospital of Qingdao University, No. 59 Haier Road, Qingdao, 266100, Shandong, China
2 shared publications - Luning Qin
Department of Cardiology, The Affiliated Hospital of Qingdao University, No. 59 Haier Road, Qingdao, Shandong, 266100, China
2 shared publications
Latest Publications
- Open Access
- 30 May 2025
- Published by Elsevier in Free Radical Biology and Medicine
- Vol. 237, 160-175
The peptide from C- Phycocyanin alleviates myocardial ischemia-reperfusion injury by suppressing ferroptosis via upregulating UCHL3
- 30 May 2025
- Published by Elsevier in Free Radical Biology and Medicine
- Vol. 237, 160-175
Open AccessThe peptide from C- Phycocyanin alleviates myocardial ischemia-reperfusion injury by suppressing ferroptosis via upregulating UCHL3
- 31 January 2025
- Published by Springer Nature in Current Treatment Options in Oncology
- Vol. 26 (2) , 103-127
Advancements in Diagnosis and Treatment of Cardiac Sarcomas: A Comprehensive Review
Opinion Statement Cardiac sarcomas are rare, aggressive malignancies originating from various cardiac cell types, presenting significant challenges in both diagnosis and treatment. This comprehensive review explores recent advancements in diagnosis and treatment of cardiac angiosarcoma, fibrosarcoma, leiomyosarcoma, and rhabdomyosarcoma. And we briefly discuss the exceedingly rare occurrence of cardiac osteosarcoma and present our perspectives on its treatment. Development of these tumors is influenced by genetic mutations, environmental factors, and chromosomal abnormalities, necessitating a multidisciplinary approach for accurate diagnosis and management. Advanced imaging techniques, biomarkers, and immunohistochemical analysis assist in confirming the diagnosis and guiding treatment decisions. Surgical resection, adjuvant therapies, and personalized treatment strategies based on genetic profiling offer promising avenues for improving patient outcomes. Emerging therapeutic approaches, such as targeted therapies and immunotherapies, have shown promising progress in recent years. Despite these advancements, the prognosis for patient with cardiac sarcomas remains poor, highlighting the urgent need for continued research to refine treatment methods and enhance long-term survival outcomes. Ongoing efforts and clinical trials are essential for advancing the management of these rare and aggressive tumors, ultimately improving quality of life for affected patients.
- 31 January 2025
- Published by Springer Nature in Current Treatment Options in Oncology
- Vol. 26 (2) , 103-127
Advancements in Diagnosis and Treatment of Cardiac Sarcomas: A Comprehensive Review
Opinion Statement Cardiac sarcomas are rare, aggressive malignancies originating from various cardiac cell types, presenting significant challenges in both diagnosis and treatment. This comprehensive review explores recent advancements in diagnosis and treatment of cardiac angiosarcoma, fibrosarcoma, leiomyosarcoma, and rhabdomyosarcoma. And we briefly discuss the exceedingly rare occurrence of cardiac osteosarcoma and present our perspectives on its treatment. Development of these tumors is influenced by genetic mutations, environmental factors, and chromosomal abnormalities, necessitating a multidisciplinary approach for accurate diagnosis and management. Advanced imaging techniques, biomarkers, and immunohistochemical analysis assist in confirming the diagnosis and guiding treatment decisions. Surgical resection, adjuvant therapies, and personalized treatment strategies based on genetic profiling offer promising avenues for improving patient outcomes. Emerging therapeutic approaches, such as targeted therapies and immunotherapies, have shown promising progress in recent years. Despite these advancements, the prognosis for patient with cardiac sarcomas remains poor, highlighting the urgent need for continued research to refine treatment methods and enhance long-term survival outcomes. Ongoing efforts and clinical trials are essential for advancing the management of these rare and aggressive tumors, ultimately improving quality of life for affected patients.
- Open Access
- 21 October 2023
- Published by Elsevier in Clinica Chimica Acta
- Vol. 551, 117613
MINOCA biomarkers: Non-atherosclerotic aspects
- 21 October 2023
- Published by Elsevier in Clinica Chimica Acta
- Vol. 551, 117613
Open AccessMINOCA biomarkers: Non-atherosclerotic aspects